Avadel Pharmaceuticals plc (AVDL)
21.64
+0.01 (0.05%)
Inactive · Last trade price on Feb 11, 2026

Avadel Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-0.28-48.83-160.28-137.46-77.337.03
Depreciation & Amortization
3.682.681.771.490.821.69
Stock-Based Compensation
18.5620.3915.817.018.873
Other Adjustments
-0.82-0.8317.1934.12-13.36-46.13
Change in Receivables
-5.34-21.99-12.1--8.28
Changes in Inventories
-8.01-9.22-9.53---1.35
Changes in Accounts Payable
4.49-4.091.55-3.114.23-2.79
Changes in Accrued Expenses
5.2516.4216.890.230.9-13.23
Changes in Other Operating Activities
-2.98-1.430.227.42-1.43-5.24
Operating Cash Flow
34.54-46.91-128.51-70.3-77.31-48.73
Capital Expenditures
----0.72-0.03-0.1
Purchases of Investments
-60.96-276-237.23-3.41-61.77-131.41
Proceeds from Sale of Investments
86.69327.78187.1483.83102.2236.28
Proceeds from Business Divestments
----16.525.5
Investing Cash Flow
10.5451.78-50.0979.756.93-69.72
Long-Term Debt Issued
--30---
Long-Term Debt Repaid
---38.67-8.65--
Net Long-Term Debt Issued (Repaid)
---8.67-8.65--
Issuance of Common Stock
5.0615.97148.36280.26179.68
Net Common Stock Issued (Repurchased)
5.0615.97148.36280.26179.68
Other Financing Activities
---4.36-4.8--
Financing Cash Flow
5.0615.97135.3414.540.26179.68
Effect of Exchange Rate Changes on Cash and Cash Equivalents
1.09-0.640.46-0.66-0.90.72
Net Cash Flow
51.2320.2-42.8123.27-21.0161.95
Beginning Cash & Cash Equivalents
-31.1773.9850.7171.729.77
Free Cash Flow
34.54-46.91-128.51-71.02-77.34-48.83
FCF Margin
13.90%-27.74%-459.58%---218.64%
Free Cash Flow Per Share
0.35-0.49-1.60-1.18-1.32-0.89
Levered Free Cash Flow
2.15-44.47-158.07-120.81-72.85-13.99
Unlevered Free Cash Flow
6.96-37.83-126.55-96.27-66.54-29.05
Updated Nov 4, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q